Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial

Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel A. Berciano-Guerrero, Luis de la Cruz, Pablo Cerezuela, Ana Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puertolas, Roberto Diaz Beveridge, Sebastian Ochenduszko, Maria-Jose Villanueva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez, Begoña Campos, Clara Montagut, Ana Drozdowskyj, Miguel A. Molina, Jose Antonio Lopez-Martin, Alfonso Berrocal
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/bcf9c314e06143fd83f1b0b564d0166e
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and cobimetinib combination as first-line treatment of patients with unresectable or metastatic advanced melanoma with BRAFV600 mutation

Ejemplares similares